Scan for early esophagus cancer using infused antibody dyes
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 study uses special drug dyes (bevacizumab and cetuximab, each tagged for imaging) during an esophagus scope to help doctors find very early abnormal cells, like low- or high-grade pre-cancer and superficial cancer. If you qualify, the goal is earlier detection and better targeting during diagnosis and treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18 years or older) and can give written consent
- You have Barrett’s esophagus without dysplasia, or with suspected/diagnosed low-grade or high-grade dysplasia, or very superficial esophageal adenocarcinoma
- You are already planning an esophagus endoscopy for diagnosis and/or treatment
- You have not had prior radiation therapy for esophageal cancer
- You have not had prior bevacizumab or cetuximab (and you do not have an allergy to these)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests less invasive ways to detect high-grade dysplasia (very abnormal cells) and esophageal cancer in people with Barrett's esophagus, a condition that can increase cancer risk. It looks for these changes using cell samples taken during a routine endoscopy, which may be quicker and more comfortable than standard biopsies.
This study tests a less invasive way to check for Barrett's esophagus and esophageal cancer. Instead of a standard endoscopy, they may use a sponge-on-a-string or other simpler methods, which could be more comfortable and easier for patients.
This trial tests if adding the antifungal drug itraconazole to standard ablation therapy can help prevent esophageal cancer in people with high-risk Barrett's esophagus. You must have a confirmed diagnosis of Barrett's esophagus with low- or high-grade dysplasia or early-stage cancer, and be planning to have ablation treatment.
This trial tests whether a special dye attached to a cancer-targeting drug can help doctors see lung nodules more clearly during a bronchoscopy. This may make it easier to find and diagnose cancer during the procedure.
This study will test whether special imaging dyes can help doctors see a protein called PD-L1 on esophageal cancer tumors. This might help guide treatment by showing whether immunotherapy drugs are likely to work.
This study tests a new imaging technology (optical biopsy) that may help doctors find early signs of esophageal cancer during a routine endoscopy. It is for people who are already scheduled for a screening procedure with a special dye (Lugol's chromoendoscopy).
Hear when a new Barrett's Esophagus Without Dysplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.